BioCryst Pharmaceuticals reports Q1 2024 financial results on May 6, 2024, with a conference call/webcast.
BioCryst Pharmaceuticals, a global biotech firm focusing on rare diseases, will report Q1 2024 financial results on May 6, 2024. Management will discuss results and provide an update during a conference call/webcast at 8:30 a.m. ET. BioCryst has commercialized ORLADEYO® (berotralstat), an oral plasma kallikrein inhibitor, and is developing small-molecule and protein therapies. Call +1 844-481-2942 (domestic) or +1 412-317-1866 (intl) for the live call, or visit www.biocryst.com for more info.
April 22, 2024
3 Articles